NeuroMetrix, Inc.
Jan 6, 2016
Add to Briefcase

NeuroMetrix Announces FDA 510(k) Clearance of Next Generation Quell® Wearable Pain Relief Technology at the 2016 Consumer Electronics Show

To be Available in March 2016

WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it received a 510(k) clearance (K152954) from the U.S. Food and Drug Administration (FDA) for an upgraded version of Quell, the company's over-the-counter, 100% drug free chronic pain relief wearable. Under this 510(k), the Quell device can be controlled directly via the Quell Relief smartphone app. This provides an unprecedented level of convenience and comfort when using Quell to treat chronic pain.

"This 510(k) further advances Quell technology by allowing the device to be conveniently and safely controlled via a smartphone," said Shai Gozani, M.D., Ph.D., President and CEO NeuroMetrix. "It is a clear example of our unwavering commitment to creating the most clinically effective and technologically innovative wearable therapeutic solution for people suffering from chronic pain. It is only fitting that we are making this announcement at CES 2016 which is the international showcase for consumer technology breakthroughs."

Quell is designed for people with a wide range of chronic pain conditions. The latest version of Quell gives users the option to control their therapy via a mobile app and includes several additional enhancements including extended battery life and advanced sleep tracking. It will be available in March 2016. NeuroMetrix will have a free upgrade program for existing Quell users who send in their previous generation devices when the new version is available in March.

NeuroMetrix is exhibiting Quell at the CES in Las Vegas from January 6 - 9, at Sands Booth #73313. Quell is a finalist for the Last Gadget Standing award, which includes some of the most breakthrough products at CES.

About NeuroMetrix

NeuroMetrix is an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
Cohn & Wolfe
Laura Wagstaff, 646-371-7595

Source: NeuroMetrix, Inc.

News Provided by Acquire Media